Publications by authors named "Laddach R"
Article Synopsis
- Anti-EGFR antibodies have limited effectiveness in breast cancer due to compensatory pathways and resistance in triple-negative breast cancer (TNBC) from CDK2/cyclin E expression; however, a cetuximab-based antibody drug conjugate (ADC) incorporating a CDK inhibitor may improve targeted treatment.
- In experimental designs, researchers evaluated the expressions of cell cycle regulators alongside EGFR and developed an ADC, combining cetuximab with CDK inhibitor SNS-032, to specifically deliver treatment to EGFR-expressing cancer cells.
- Results showed that the ADC effectively inhibited tumor growth, induced cytotoxic effects on high EGFR-expressing cells, and demonstrated potential for improved targeting in aggressive breast cancer types, highlighting the importance
Article Synopsis
- - B cells play a crucial role in the immune response against tumors, particularly in melanoma, but their specific functions and characteristics have not been fully explored until now.
- - In this study, researchers found that memory B cells are more prevalent in tumors than in the bloodstream and exhibit unique antibody profiles that indicate processes like clonal expansion and affinity maturation.
- - The presence of tumor-associated B cells with autoimmune-like traits and high levels of antibodies related to both autoimmune diseases and cancer suggests a dysregulated immune response in melanoma patients.
Article Synopsis
- Despite existing checkpoint inhibitor therapies, about half of melanoma patients still struggle with poor outcomes.
- A new engineered monoclonal IgE antibody targeting the CSPG4 antigen shows promise by binding to melanoma cells and enhancing immune responses.
- In studies, this IgE therapy significantly improved survival and anti-tumor activity in models, suggesting its potential as an effective treatment option for melanoma patients.
Background: Survival rates for ovarian cancer remain poor, and monitoring and prediction of therapeutic response may benefit from additional markers. Ovarian cancers frequently overexpress Folate Receptor alpha (FRα) and the soluble receptor (sFRα) is measurable in blood. Here we investigated sFRα as a potential biomarker.
View Article and Find Full Text PDFThe application of monoclonal antibodies (mAbs) for the treatment of melanoma has significantly improved the clinical management of this malignancy over the last decade. Currently approved mAbs for melanoma enhance T cell effector immune responses by blocking immune checkpoint molecules PD-L1/PD-1 and CTLA-4. However, more than half of patients do not benefit from treatment.
View Article and Find Full Text PDFArticle Synopsis
- * In melanoma patients, TGF-β-expressing B cells form clusters in the tumor microenvironment and interact with T cells and regulatory T cells (Tregs) through specific signals, suggesting a complex relationship that can contribute to immune suppression.
- * The study highlights how B cells from melanoma patients may promote Treg differentiation and support T-helper cell functions, particularly when combined with anti-PD-1 treatment, indicating potential therapeutic implications for boosting anti-tumor immunity.
Novel drug-target interactions via link prediction and network embedding.
BMC Bioinformatics
April 2022
Background: As many interactions between the chemical and genomic space remain undiscovered, computational methods able to identify potential drug-target interactions (DTIs) are employed to accelerate drug discovery and reduce the required cost. Predicting new DTIs can leverage drug repurposing by identifying new targets for approved drugs. However, developing an accurate computational framework that can efficiently incorporate chemical and genomic spaces remains extremely demanding.
View Article and Find Full Text PDFIn breast cancer, humoral immune responses may contribute to clinical outcomes, especially in more immunogenic subtypes. Here, we investigated B lymphocyte subsets, immunoglobulin expression, and clonal features in breast tumors, focusing on aggressive triple-negative breast cancers (TNBC). In samples from patients with TNBC and healthy volunteers, circulating and tumor-infiltrating B lymphocytes (TIL-B) were evaluated.
View Article and Find Full Text PDFThe contributions of the humoral immune response to melanoma are now widely recognized, with reports of positive prognostic value ascribed to tumor-infiltrating B cells (TIL-B) and increasing evidence of B cells as key predictors of patient response to treatment. There are disparate views as to the pro- and anti-tumor roles of B cells. B cells appear to play an integral role in forming tumor-associated tertiary lymphoid structures (TLSs) which can further modulate T cell activation.
View Article and Find Full Text PDFCytotoxic T-lymphocyte associated protein-4 (CTLA-4) and the Programmed Death Receptor 1 (PD-1) are immune checkpoint molecules that are well-established targets of antibody immunotherapies for the management of malignant melanoma. The monoclonal antibodies, Ipilimumab, Pembrolizumab, and Nivolumab, designed to interfere with T cell inhibitory signals to activate immune responses against tumors, were originally approved as monotherapy. Treatment with a combination of immune checkpoint inhibitors may improve outcomes compared to monotherapy in certain patient groups and these clinical benefits may be derived from unique immune mechanisms of action.
View Article and Find Full Text PDFArticle Synopsis
- IgE plays a crucial role in enhancing the immune response during infections and has been shown to aid monocyte and macrophage recruitment, which is important for fighting tumors.
- The study found that IgE stimulation of human monocytes leads to the activation of pro-inflammatory signals and improved tumor-killing functions, which could be beneficial for cancer treatment.
- Insights from this research can help develop new IgE monoclonal antibody therapies aimed at boosting immune responses against cancer.
We determined the CCR5 chemokine receptor and cytochrome P450 aromatase (P450arom) transcript copies number in swim-up sperm isolated from fertile and infertile men. The ejaculates were purified by centrifugation through discontinuous Percoll density gradient and swim-up techniques. RNA was isolated from sperm, treated with DNase I and reverse-transcribed into cDNA.
View Article and Find Full Text PDFObjective: To determine the upregulation of transcript and protein levels of the T cell receptor (TCR)/CD3-Fc-gammaR chain in CD4+ T cells of systemic lupus erythematosus (SLE) patients with different clinical disease activity scored on the SLE Disease Activity Index (SLEDAI) scale.
Methods: CD4+ cells were isolated by the positive biomagnetic separation technique. Quantitative analysis of Fc-gammaR cDNA was carried out by using the real-time quantitative polymerase chain reaction (RQ-PCR) SYBR Green I system.